Novel Non-hallucinogenic Neurite Growth Compounds as 5‑HT2A Agonists for Treating Stress-Related Disorders, Namely Depression, Anxiety, and PTSD.
ACS Medicinal Chemistry Letters July 30, 2025 DOI: 10.1021/acsmedchemlett.5c00440 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Anxiety Depression PTSD |
Abstract
Provided herein are novel non-hallucinogenic neurite growth compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating stress-related disorders, namely depression, anxiety, and post-traumatic stress disorder (PTSD), and processes for preparing such compounds.
Citations in the library
Cites 4
- 5-HT2A receptors: Pharmacology and functional selectivity. Pharmacological Reviews April 23, 2025
- Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications. Brain Sciences January 25, 2025
- Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature. Brain Research 2025
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025